Sagent Pharmaceuticals Reports Second Quarter 2012 Financial Results

Sagent Pharmaceuticals SGNT, today announced financial results for the quarter ended June 30, 2012. Second Quarter 2012 Highlights:
Revenue increased 32% to $42.7 million driven by products launched in the last twelve months;
Reported gross profit increased to $6.5 million, or 15.2% inclusive of $1.2 million of margin from the sale of heparin inventory previously written off through excess inventory reserves;
Launched Atracurium Besylate and Irinotecan; and
Key manufacturing partner's facility found acceptable by FDA, clearing pathway for multiple product approvals and four to six new product launches during the second half of 2012.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsPre-Market Outlook
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!